Expert Interview
A Second View: Examining ImmuityBio's novel therapeutic approach to BCG-unresponsive high grade NMIBC combining Anktiva (N-803) with intravesical BCG and its recent Phase 2/3 QUILT3.032 Trial results presented at ASCO-GU
Ticker(s): IBRXInstitution: BCG Oncology
- President of BCG Oncology in Phoenix, Arizona.
- Practice is >70% bladder cancer and has seen >800 patients with NMIBC.
- Awarded the initial NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial which resulted in the first controlled trial demonstrating the efficacy of intravesical BCG immunotherapy.
- Worked on and published experience with hyperthermic dose dense combination gemcitabine and docetaxel.
Roughly how many patients with NMIBC do you currently manage?
Added By: c_adminOn a scale from 1 -10 (10 being extremely excited) where would you rate your level of excitement for Immunity Bio's combo therapy?
Added By: c_adminWill this trial be submitted for regulatory approval? If so, the trial lacks a control arm will this be viewed negatively by FDA and will they require a new Phase 3 trial to be run? For a Phase 3 trial what would be the best active comparator (standard-of-care) to use for the control arm?
Added By: c_adminAre there any future therapies in the pipeline for which you are excited about?
Added By: c_adminHave you used pembrolizumab (recently approved for NMIBC) and do you see a place for immuno-oncology agents in high-risk disease?
Added By: c_adminWhat is the current standard of care in NMIBC?
Added By: c_adminHow is the field being impacted by supply shortages of BCG?
Added By: c_adminWhat current treatment options are the most utilized by physicians?
Added By: c_adminGiven this is a combination treatment of N-803 + BCG, will N-803 monotherapy ever be evaluated to understand single-agent efficacy?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
